A
KALV

AlphaQuest’s KalVista Pharmaceuticals KALV Stock Holding History

AlphaQuest’s Portfolio KALV Stock Details KALV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-52,190
Closed -$843K – 1042
2025
Q4 		$843K Buy
52,190
+415
+0.8% +$5.5K 0.05% 518
2025
Q3 		$631K Buy
51,775
+51,644
+39,423% +$714K 0.04% 653
2025
Q2 		$1.48K Buy
+131
New +$1.6K ﹤0.01% 1926
2025
Q1 		– Sell
-17,700
Closed -$150K – 2049
2024
Q4 		$150K Buy
17,700
+2,588
+17% +$26.8K 0.02% 974
2024
Q3 		$175K Buy
+15,112
New +$190K 0.02% 1115
2024
Q2 		– Sell
-1,800
Closed -$21.3K – 1734
2024
Q1 		$21.3K Buy
+1,800
New +$24K ﹤0.01% 1028

Other funds holding KALV

VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SCM
Silverarc Capital Management Boston, Massachusetts $980M AUM 470.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

AlphaQuest's KALV Position: Q1 2026 in Review

AlphaQuest sold out of KalVista Pharmaceuticals (KALV) in Q1 2026, closing a stake of 52,190 shares — an estimated $843K sold.

AlphaQuest first reported a position in KALV in Q1 2024 and held it in 6 quarters. The position peaked at $843K in Q4 2025. 183 funds tracked by Wall St. Rank hold KALV as of Q1 2026.

  • AlphaQuest reported no remaining KalVista Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • AlphaQuest sold 52,190 KalVista Pharmaceuticals shares in Q1 2026, an estimated $843K.
  • AlphaQuest first reported a position in KalVista Pharmaceuticals in Q1 2024 and held it in 6 quarters.
  • AlphaQuest's KalVista Pharmaceuticals position peaked at $843K in Q4 2025.
  • 183 funds tracked by Wall St. Rank held KalVista Pharmaceuticals as of Q1 2026.

Based on AlphaQuest's 13F filing for Q1 2026.